Thanh U. Barbie

Brigham and Women's Hospital — United States

Immunology and Microbiology · Life Sciences

14h-index1.8kcitations104works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(23), Cancer Immunotherapy and Biomarkers(22), Cytokine Signaling Pathways and Interactions(22), Lung Cancer Treatments and Mutations(12), HER2/EGFR in Cancer Research(11)

Publications104 total

Figure_S11 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S12 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Supplementary Table S1 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S4 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S7 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S3 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Data from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S10 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S1 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S13 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S6 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S5 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Supplementary Table S2 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S9 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S2 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Figure_S8 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
2025Open Access
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Cancer Immunology Research·2025Open Access
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform
Cell Reports Medicine·2025· 4 citedOpen Access
Intraoperative Supine Breast MRI for Residual Tumor Assessment after Breast-Conserving Therapy in Early-Stage Breast Cancer
Radiology Imaging Cancer·2025· 2 citedOpen Access
Data from <i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
2024· 1 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

David A. Barbie(38), Tran C. Thai(31), Cloud P. Paweletz(28), Prafulla C. Gokhale(21), Navin R. Mahadevan(19), Kwok‐Kin Wong(17), Shunsuke Kitajima(14), Marco Campisi(14), Pasi A. Jänne(14), Andrew Portell(13), Zehua Li(13), Elena P. Ivanova(11), Amir Reza Aref(10), Elena V. Ivanova(10), Patrick H. Lizotte(9), Russell W. Jenkins(8), Michaela Bowden(8), Diana Miao(8), Gao Zhang(8), Zhi Wei(8)